Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A New Breast Cancer MRI Biomarker Using the Intrinsic T1rho Signal

NCT05486520 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05486520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05486520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A New Breast Cancer MRI Biomarker Using the Intrinsic T1rho Signal
Lead sponsor
Massachusetts General Hospital
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
September 1, 2022
Completion date
October 1, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast benign, breast malignant tumor, malignant neoplasm of breast